Nortis, Inc.
Woodinville, WA · Founded 2007 · CIK 0001416214 · Medtech · Acquired
Software consulting and technology advisory services
nortisbio.com →- Grants
- $9.6M
- 16 awards
- Sector median: 1
- Raised
- $11M
- 11 Form D · Aug 2022
- 50 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $13,000 | |
| Private capital raised | Form D · SEC | $15,000 | |
| Private capital raised | Form D · SEC | $10,000 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $408,845 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an Advanced In-Vitro Model for Angiogenesis Research and Drug Test | $739,884 | |
| Federal grant | Department of Health and Human Services · Phase II · A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A microfluidic quality-control assay for stem-cell derived therapies | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Microfluidic Platform for Stem Cell Applications | $365,000 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | $700,895 | |
| Federal grant | Department of Health and Human Services · Phase II · A microfluidic platform for modeling drug transport and cell trafficking across the blood brain barrier | $1,388,626 | |
| Federal grant | Department of Health and Human Services · Phase II · A microfluidic platform for modeling drug transport and cell trafficking across the blood-brain barrier | $687,731 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule | $331,413 | |
| Federal grant | Department of Health and Human Services · Phase I · Organ-on-chip based assays for personalized assessment of renal resilience in aging patients | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule | $1,024,842 | |
| Federal grant | Department of Health and Human Services · Phase II · Organ-on-Chip Approach for Assessing Tissue-specific SARS-CoV-2 Infection and Response to Antiviral Therapy | $255,716 | |
| Federal grant | Department of Health and Human Services · Phase II · Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | $252,114 | |
| Federal grant | Department of Health and Human Services · Phase II · Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | $876,058 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $1,500,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of pharmacokinetic assays utilizing an organ-on-chip model of the human kidney proximal tubule | $1,024,820 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening | $803,596 | |
| Private capital raised | Form D · SEC | $6,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds | $275,453 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2195 | Mozaic Medical Inc | — | $225K |
| 2196 | Aikili Biosystems Inc | — | — |
| 2197 | NEOCHORD INC | — | $63M |
| 2198 | Nortis, Inc. | — | $11M |
| 2199 | Biorasis | — | — |
| 2200 | DOTS Devices | — | — |
| 2201 | OXYLO, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul ConleyDirector
- Greg CoronaDirector
- Sharon EversonDirector
- Kriss HammondDirector
- Mary HarrisonDirector
- Alan NelsonDirector · Executive Officer · Promoter
- Thomas NeumannDirector · Executive Officer
- Susan PrestonDirector
- Walter RobbDirector · Promoter
- Makoto ShintaniDirector
Patents
- Microfluidic System for Reproducing Functional Units of Tissues and Organs In Vitroapplication
- Method For Vascularizing In-vitro Generated Or Ex-vivo Tissue Fragments In A Microfluidic Deviceapplication
- Microfluidic System for Reproducing Functional Units of Tissues and Organs In Vitroapplication
- Modular Microfluidic System For Perfused Cell Cultureapplication
- Method For Vascularizing In-vitro Generated Or Ex-vivo Tissue Fragments In A Microfluidic Deviceapplication
- Microfluidic System For Reproducing Functional Units Of Tissues And Organs In Vitroapplication
- Method For Creating Perfusable Microvessel Systemsapplication
- Method For Creating Perfusable Microvessel Systemsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.